Molecular profiling of CD34+ cells identifies low expression of CD7, along with high expression of proteinase 3 or elastase, as predictors of longer survival in patients with CML
- 1 January 2006
- journal article
- Published by American Society of Hematology in Blood
- Vol. 107 (1), 205-212
- https://doi.org/10.1182/blood-2005-05-2155
Abstract
Although most patients with chronic myeloid leukemia (CML) have the same initial molecular abnormality, the BCR-ABL fusion gene, the duration of chronic phase (CP) varies widely. To identify the possible molecular basis of this heterogeneity, we studied CD34+ cells collected at diagnosis from 68 patients with CML-CP. By using oligonucleotide microarray screening, we performed gene-expression profiling on 2 subsets of patients, one comprising patients with an “aggressive disease” who developed blastic transformation (BT) within 3 years of diagnosis (n = 10) and, at the other extreme, patients with an “indolent disease” whose BT occurred 7 or more years from diagnosis (n = 9). This screening revealed 20 genes differentially expressed in patients with aggressive and indolent disease, which were validated by quantitative reverse transcriptase/polymerase chain reaction (Q-RT/PCR). A multivariate Cox regression model identified the combination of low CD7 expression with high expression of proteinase 3 or elastase as associated with longer survival in the complete cohort of 68 patients. This differential pattern of gene expression probably reflects the intrinsic heterogeneity of the disease; if so, assessing expression levels of selected genes at diagnosis may be valuable in predicting duration of survival in patients treated with imatinib and the newer tyrosine kinase inhibitors.Keywords
This publication has 43 references indexed in Scilit:
- Dynamics of chronic myeloid leukaemiaNature, 2005
- Monitoring patients in complete cytogenetic remission after treatment of CML in chronic phase with imatinib: patterns of residual leukaemia and prognostic factors for cytogenetic relapseLeukemia, 2005
- Inhibition of wild-type and mutant Bcr-Abl by AP23464, a potent ATP-based oncogenic protein kinase inhibitor: implications for CMLBlood, 2004
- Telomere Shortening Correlates with Prognostic Score at Diagnosis and Proceeds Rapidly during Progression of Chronic Myeloid LeukemiaLeukemia & Lymphoma, 2004
- Overriding Imatinib Resistance with a Novel ABL Kinase InhibitorScience, 2004
- Identification and in vitro expansion of CD4+ and CD8+ T cells specific for human neutrophil elastaseBlood, 2004
- CD7 expression by CD34+ cells in CML patients, of prognostic significance?European Journal of Haematology, 2003
- Double jeopardy from a single translocation: deletions of the derivative chromosome 9 in chronic myeloid leukemiaBlood, 2003
- Exploration, normalization, and summaries of high density oligonucleotide array probe level dataBiostatistics, 2003
- Imatinib Compared with Interferon and Low-Dose Cytarabine for Newly Diagnosed Chronic-Phase Chronic Myeloid LeukemiaNew England Journal of Medicine, 2003